WARNING: This product is for research use only, not for human or veterinary use.
MedKoo CAT#: 205998
CAS#: 309915-12-6 (HCl)
Description: Talmapimod, also known as SCIO-469, is an orally bioavailable, small-molecule, p38 mitogen-activated protein kinase (MAPK) inhibitor with potential immunomodulating, anti-inflammatory, and antineoplastic activities. Talmapimod specifically binds to and inhibits the phosphorylation of p38 MAPK, which may result in the induction of tumor cell apoptosis, the inhibition of tumor cell proliferation, and the inhibition of tumor angiogenesis. This agent may also enhance proteasome inhibitor-induced apoptosis.
MedKoo Cat#: 205998
Name: Talmapimod HCl
CAS#: 309915-12-6 (HCl)
Chemical Formula: C27H31Cl2FN4O3
Molecular Weight: 549.47
Elemental Analysis: C, 59.02; H, 5.69; Cl, 12.90; F, 3.46; N, 10.20; O, 8.74
Talmapimod HCl, purity > 98%, is in stock. Current shipping out time is about 2 weeks after order is received. CoA, QC data and MSDS documents are available in one week after order is received. Delivery time: overnight (USA/Canada); 3-5 days (worldwide).
Synonym: SCIO469, SCIO-469, SCI O469, Talmapimod, Talmapimod HCl
IUPAC/Chemical Name: 2-(6-chloro-5-((2R,5S)-4-(4-fluorobenzyl)-2,5-dimethylpiperazine-1-carbonyl)-1-methyl-1H-indol-3-yl)-N,N-dimethyl-2-oxoacetamide hydrochloride
InChi Key: FOJUFGQLUOOBQP-MCJVGQIASA-N
InChi Code: InChI=1S/C27H30ClFN4O3.ClH/c1-16-13-33(17(2)12-32(16)14-18-6-8-19(29)9-7-18)26(35)21-10-20-22(25(34)27(36)30(3)4)15-31(5)24(20)11-23(21)28;/h6-11,15-17H,12-14H2,1-5H3;1H/t16-,17+;/m0./s1
SMILES Code: O=C(N(C)C)C(C1=CN(C)C2=C1C=C(C(N3[C@H](C)CN(CC4=CC=C(F)C=C4)[C@@H](C)C3)=O)C(Cl)=C2)=O.[H]Cl
The following data is based on the product molecular weight 549.47 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
|Concentration / Solvent Volume / Mass||1 mg||5 mg||10 mg|
|1 mM||1.15 mL||5.76 mL||11.51 mL|
|5 mM||0.23 mL||1.15 mL||2.3 mL|
|10 mM||0.12 mL||0.58 mL||1.15 mL|
|50 mM||0.02 mL||0.12 mL||0.23 mL|
1: Sokol L, Cripe L, Kantarjian H, Sekeres MA, Parmar S, Greenberg P, Goldberg SL, Bhushan V, Shammo J, Hohl R, Verma A, Garcia-Manero G, Li YP, Lowe A, Zhu J, List AF. Randomized, dose-escalation study of the p38α MAPK inhibitor SCIO-469 in patients with myelodysplastic syndrome. Leukemia. 2012 Sep 11. doi: 10.1038/leu.2012.264. [Epub ahead of print] PubMed PMID: 23032694.
2: Genovese MC, Cohen SB, Wofsy D, Weinblatt ME, Firestein GS, Brahn E, Strand V, Baker DG, Tong SE. A 24-week, randomized, double-blind, placebo-controlled, parallel group study of the efficacy of oral SCIO-469, a p38 mitogen-activated protein kinase inhibitor, in patients with active rheumatoid arthritis. J Rheumatol. 2011 May;38(5):846-54. doi: 10.3899/jrheum.100602. Epub 2011 Feb 1. PubMed PMID: 21285160.
3: Laufer S, Lehmann F. Investigations of SCIO-469-like compounds for the inhibition of p38 MAP kinase. Bioorg Med Chem Lett. 2009 Mar 1;19(5):1461-4. doi: 10.1016/j.bmcl.2009.01.023. Epub 2009 Jan 14. PubMed PMID: 19195885.
4: Nikas SN, Drosos AA. SCIO-469 Scios Inc. Curr Opin Investig Drugs. 2004 Nov;5(11):1205-12. Review. PubMed PMID: 15573872.